By Kathryn Calkins
Staff Writer

Some companies targeting opportunistic diseases that strike AIDS patients have witnessed declines in their disease populations following the advent of triple combination therapies. One such condition is AIDS-related diarrhea. Two companies, Galagen Inc. (GGEN, Arden Hills, Minn.) and ImmuCell Corp. (ICCC, Portland, Maine) last year suspended their trials in the condition, citing difficulty enrolling patients. A third company, LXR Biotechnology Inc. (LXR, Richmond, Calif.), never actually started a trial, also because of anticipated difficulty with enrollment.